Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
David-Neto E et al. | Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. | 2017 | Transplantation | pmid:27798513 |
Hernández D et al. | Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. | 2007 | Transplantation | pmid:17893603 |
Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
Prókai à et al. | Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. | 2016 | Transplantation | pmid:26502369 |
Singh N et al. | Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. | 2000 | Transplantation | pmid:10708096 |
Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
Haririan A et al. | Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. | 2003 | Transplantation | pmid:12717201 |
Gonwa T et al. | Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. | 2003 | Transplantation | pmid:12717205 |
Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
Han DH et al. | Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. | 2010 | Transplantation | pmid:20562737 |
Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
Kim CD et al. | Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. | 2010 | Transplantation | pmid:20842074 |
Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
Demetris AJ et al. | Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. | 1992 | Transplantation | pmid:1374944 |
Al-Uzri A et al. | Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). | 2001 | Transplantation | pmid:11579294 |
Manitpisitkul W et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. | 2009 | Transplantation | pmid:19584685 |
Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
Dominguez J et al. | Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. | 2000 | Transplantation | pmid:11063349 |
Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
Esquivel CO et al. | Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. | 1996 | Transplantation | pmid:8607198 |
Abu-Qaoud MS et al. | Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. | 2012 | Transplantation | pmid:23044666 |
Hoogduijn MJ et al. | Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. | 2008 | Transplantation | pmid:19005411 |
Heidt S et al. | Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. | 2008 | Transplantation | pmid:19005412 |
Merkle M et al. | The effect of sevelamer on tacrolimus target levels. | 2005 | Transplantation | pmid:16177649 |
Tzakis AG et al. | Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. | 2004 | Transplantation | pmid:15114087 |
Bechstein WO et al. | Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. | 2004 | Transplantation | pmid:15114089 |
Talbot D et al. | Alopecia as a consequence of tacrolimus therapy in renal transplantation? | 1997 | Transplantation | pmid:9415574 |
Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
Egawa H et al. | Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. | 1995 | Transplantation | pmid:7533958 |
Demmers MW et al. | Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. | 2014 | Transplantation | pmid:24157471 |
Wallia A et al. | Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. | 2010 | Transplantation | pmid:20098286 |
McDiarmid SV et al. | Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. | 1993 | Transplantation | pmid:7685933 |
Lauria MW et al. | Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. | 2010 | Transplantation | pmid:20061923 |
Gullestad L et al. | Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. | 2010 | Transplantation | pmid:20061999 |
Pascual M et al. | Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. | 1998 | Transplantation | pmid:9869086 |
Strumph P et al. | The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. | 1995 | Transplantation | pmid:7542815 |
Kasahara M et al. | Role of HLA compatibility in pediatric living-related liver transplantation. | 2002 | Transplantation | pmid:12438966 |
Hudnall SD | Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? | 2002 | Transplantation | pmid:12369583 |
Arai K et al. | Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. | 1989 | Transplantation | pmid:2479130 |
Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
Chan L et al. | Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | 2008 | Transplantation | pmid:18360262 |
Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
de Jonge H et al. | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. | 2010 | Transplantation | pmid:20592652 |
Yuzawa K and Fukao K | Topical FK506 ointment for skin grafting. | 1998 | Transplantation | pmid:9565111 |
Puig I Marà JM et al. | Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. | 2000 | Transplantation | pmid:10919604 |
Erickson LM et al. | Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. | 2003 | Transplantation | pmid:12923448 |
Wong W et al. | 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? | 2005 | Transplantation | pmid:16082321 |
Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |